Abexinostat showed a 69.5% objective response rate in relapsed follicular lymphoma patients.
New Drug Shrinks Stubborn Lymphoma Tumors After Other Treatments Fail
This single-arm, multi-center phase 2 study evaluated abexinostat in 90 patients with relapsed or refractory follicular lymphoma who had rec…
A new treatment is helping some patients with stubborn lymphoma shrink tumors and stay in control for over a year, even after other therapie…
Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates.
New treatments show high response rates for advanced follicular lymphoma patients
This systematic review and meta-analysis evaluated outcomes for patients with follicular lymphoma experiencing disease progression within 24…
New powerful medicines help 91% of advanced follicular lymphoma patients whose disease returned quickly after treatment.
R-CVP after radiotherapy improves progression-free survival in early-stage follicular lymphoma
Can adding a drug cocktail to radiation help keep early lymphoma from returning?
In a multicenter RCT with 150 patients with early-stage follicular lymphoma and 11.3-year median follow-up, involved-field radiotherapy plus…
Adding R-CVP drugs to radiation therapy helps early-stage lymphoma patients stay cancer-free longer, with mostly temporary side effects and …